In a groundbreaking leap forward in the fight against drug-resistant bacteria, Kinvard Bio is pioneering a new class of antibiotics that could revolutionize the treatment landscape for infections deemed untreatable.As traditional antibiotics lose efficacy due to increasing antimicrobial resistance, this innovative startup, born from the prestigious Myers Lab at Harvard University, aims to address one of the most pressing health crises of our time.